About Pharvaris N.V.

Pharvaris N.V., founded in 2015 and based in the Netherlands with operations in Switzerland, is pioneering the development of oral small molecule drugs for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company was established by experienced biotech entrepreneurs who recognized the significant unmet need for convenient, effective oral therapies in HAE, a rare genetic disorder causing unpredictable and potentially life-threatening swelling attacks. PHVS stock price reflects investor optimism about the company's potential to transform HAE treatment with its innovative oral therapy approach.

Led by CEO Berndt Modig, who brings over 25 years of experience in the pharmaceutical industry including leadership roles at orphan drug companies, Pharvaris has assembled a world-class team of drug developers and HAE experts. The management team's deep understanding of rare disease drug development and commercialization, combined with strong relationships in the HAE community, positions the company to advance its pipeline efficiently. Leadership's strategic vision and execution capabilities have been instrumental in securing funding and partnerships that support PHVS stock price appreciation potential.

Pharvaris is developing an innovative portfolio of oral bradykinin B2-receptor antagonists, with lead candidates in clinical trials for both on-demand treatment and prophylactic prevention of HAE attacks. The company's proprietary SNAC technology enables oral delivery of molecules that would otherwise require injection, potentially offering patients unprecedented convenience and control over their disease management. With the HAE treatment market expected to grow significantly and current therapies primarily limited to injectable options, PHVS represents an attractive investment opportunity in the orphan drug space, offering potential for premium pricing and market exclusivity if successful in bringing the first oral therapies to market.